Brean Capital Reiterates a Buy Rating on MiMedx Group

By George MacDonald

In a report released today, Jason Wittes from Brean Capital reiterated a Buy rating on MiMedx Group (NASDAQ: MDXG), with a price target of $12. The company’s shares opened today at $8.09.

Wittes wrote, “Yesterday morning MDXG announced 4Q15 and FY2015 results. Top-line results were as preliminarily reported with revenues of $51.8 million (+31% growth YoY), and EPS beat consensus of $0.06 by six cents at $0.12. DSOs increased to 93 days this quarter over 86 days last quarter due to continued expansion of customer base and a realignment of their network of distributors. The company reiterated its previous 1Q16 and FY2016 guidance: 1Q16 revenues of $55.5-$58 million and FY2016 revenues and adjusted EPS of $260-$270 million and $0.33- $0.37, respectively.”

MiMedx Group has an analyst consensus of Strong Buy.

MiMedx Group`s market cap is currently $884.8M and has a P/E ratio of 47.7. The company has a book value ratio of 9.02%.

Unlike Brean Capital`s latest rating, based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is neutral on the stock. Most recently, in November 2015, Charles Robert Evans, a a Director at MDXG bought 10,000 shares for a total of $78,300.

According to TipRanks.com, Wittes is a 1-star analyst with an average return of -4.1% and a 35.5% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Zimmer Biomet Holdings, and Xtant Medical Holdings.

MiMedx Group Inc is a developer, manufacturer and marketer of patent-protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.